Ethosuximide-d5
(Synonyms: CI-366-d5, NSC 64013-d5) 目录号 : GC47315
An internal standard for the quantification of ethosuximide
Cas No.:1989660-59-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Ethosuximide-d5 is intended for use as an internal standard for the quantification of ethosuximide by GC- or LC-MS. Ethosuximide is an anticonvulsant.1,2,3,4,5 It increases glucose, fructose-1,6-bisphosphate, and pyruvate levels in rat brain when administered at a dose of 200 mg/kg.1 Ethosuximide (400 mg/kg) reduces the severity of audiogenic seizures in a rat model of barbiturate withdrawal-induced convulsions.2 It also inhibits tonic hindlimb extension induced by pentylenetetrazole or brainstem stimulation (ED50s = 35 and 70 mg/kg, respectively), as well as leptazol-induced clonic seizures (ED50 = 230 mg/kg), in rats.3,4 Ethosuximide reduces resting tremor by 60% in a macaque model of Parkinson's disease induced by MPTP when administered at a dose of 150 mg/animal for 5 days.5 Formulations containing ethosuximide have been used in the treatment of petit mal seizures.
1.Nahorski, S.R.Biochemical effects of the anticonvulsants trimethadione, ethosuximide and chlordiazepoxide in rat brainJ. Neurochem.19(8)1937-1946(1972) 2.Norton, P.R.The effects of drugs on barbiturate withdrawal convulsions in the ratJ. Pharm. Pharmacol.22(10)763-766(1970) 3.Consroe, P.F., and Wolkin, A.L.Anticonvulsant interaction of cannabidiol and ethosuximide in ratsJ. Pharm. Pharmacol.29(8)500-501(1977) 4.Chiu, P., and Burnham, W.M.The effect of anticonvulsant drugs on convulsions triggered by direct stimulation of the brainstemNeuropharmacology21(4)355-359(1982) 5.Gomez-Mancilla, B., Latulippe, J.F., Boucher, R., et al.Effect of ethosuximide on rest tremor in the MPTP monkey modelMov. Disord.7(2)137-141(1992)
| Cas No. | 1989660-59-4 | SDF | |
| 别名 | CI-366-d5, NSC 64013-d5 | ||
| Canonical SMILES | O=C1CC(C([2H])([2H])C([2H])([2H])[2H])(C)C(N1)=O | ||
| 分子式 | C7H6D5NO2 | 分子量 | 146.2 |
| 溶解度 | Methanol: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 6.8399 mL | 34.1997 mL | 68.3995 mL |
| 5 mM | 1.368 mL | 6.8399 mL | 13.6799 mL |
| 10 mM | 0.684 mL | 3.42 mL | 6.8399 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。